M alignant melanoma is a tumor resulting from the malignant transformation of melanocytes or tanning cells. It is the most lethal type of skin tumor and its incidence is rising very fast [1] . The main and often necessary treatment of malignant melanoma is surgical removal. Moreover, numerous adjuvant immunotherapeutic strategies have been developed [2] . Interferon-alpha-2b (IFN-alpha) is an adjuvant treatment for patients with malignant melanoma at high risk of recurrence [3, 4] . Melanoma patients often experience adjustment difficulties, including distress; fear of death, recurrence or progression of disease; changes in quality of life and social relationships; and finally, depressive or anxiety disorders [5] . In addition, interferon is associated with a number of toxicities, including adverse effects on the central nervous system [6] . During treatment, interferon may cause severe neuropsychiatric syndromes, such as depressive symptoms, cognitive disturbances, chronic fatigue syndrome, dysphoria, anxiety symptoms, anorexia, mania and psychotic states [7] [8] [9] [10] . It is difficult to define the relationship between IFN-alpha treatment and neuropsychiatric complications because there is a lack of specific studies. The mechanisms by which IFN-alpha is able to influence brain function are unclear, but several hypotheses had been proposed. First, interferon is able to produce depressive symptoms through the central serotoninergic system [11] . Second, by enhancing the production of hormones of the hypothalamic-pituitary-axis (HPA), such as corticotrophin releasing factor (CRF), because overproduction of CRF causes symptoms such anxiety, anorexia, weight loss, changes in sexual behavior, changes in body care activities and changes in sleeping pattern [12] . Finally, interferon stimulates the production of proinflamatory cytokines, which may also activate the HPA axis [13] . However, the risk of depression induced by interferon is difficult to assess. Interferon-induced depression may be connected with depressive adjustment disorders starting at the beginning of treatment (figure 1). These problems are more concerned with the announcement of the diagnosis or with relapse of the illness, and its seriousness than with the toxicity of the IFN-alpha molecule [14] . Nevertheless, there seems to be a relationship between the prescription of interferon and the appearance of psychic disorders [14] . On the other hand, both melanoma and interferon treatment can provoke fatigue, irritability, anorexia, and other manifestations also seen in depression [15] . Moreover, interferon is often part of a combined drug treatment that may show additive toxicities [2] . The aim of this prospective study was to illustrate clinical and management differences between primary and IFNinduced depressive disorders in all inpatients with malignant melanoma treated with IFN-alpha and referred to the psychiatry consultation-liaison team during a two year period.
Methods
The sample included all consecutive inpatients with malignant melanoma treated with IFN-alpha-2b referred to the psychiatric consultation-liaison service during a two year period in a general teaching hospital (Hospital Clínic, Barcelona, Spain). Each patient was interviewed in private on the dermatology ward using a semi-structured interview. Moreover, at the initial psychiatric evaluation, the Global Assessment of Functioning (GAF) and the Clinical Global Impression-Severity of Illness (CGI-S) scale were scored. At the end of hospitalization the Clinical Global Impression-Improvement of Illness (CGI-I) was scored. Written informed consent was obtained. The study protocol was approved by the institutional review board. The semi-structured interview included sociodemographic and clinical variables: melanoma stage and adjuvant therapy received; reasons for referral; time of onset; current psychiatric diagnosis, lifetime psychiatric diagnosis, and type and dosage of psychopharmacological treatment prescribed. Diagnostic assessment was formulated according to the revised fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR; American Psychiatric Association, 2000). Assignment of the current psychiatric DSM-IV diagnosis required agreement between all the consultation-liaison psychiatric staff involved in each case (a psychiatrist in training, a psychiatry nurse and a senior consultant). The GAF is an observer-based rating scale for the current overall functioning of a patient on a continuum from the most severe mental disorder to complete mental health that was defined as Axis V of the DSM-IV-R. Scale values range from 1 (sickest individual) to 100 (the healthiest individual) [16] . A score of 100 on GAF means superior functioning whereas a score of 40 or below means some impairment in reality testing and communication or major impairment in several areas, such as work or school, family relations, judgment, thinking, or mood. The CGI-S scale was used to rate psychiatric illness severity [17] . The CGI-S scale requires the clinician to rate the severity of the patient's illness on a seven-point scale in which, 1 is normal (not at all ill); 2 is borderline mentally ill; 3 is mildly ill; 4 is moderately ill; 5 is markedly ill; 6 is severely ill; and 7 is among the most extremely ill. The CGI-I scale was used to rate psychiatric illness severity [17] . The CGI-I scale is a clinician-assessed sevenpoint score that ranges from 1 ("very much improved") to 7 ("very much worse"); 2 is much improved; 3 is minimally improved; 4 is no change; 5 is minimally worse; 6 much worse. Statistical analyses of data were carried out following a descriptive study according to the statistical program SPSS.12 v. Yates corrected chi-square contingency test (x 2 ) between the adjustment disorder group and the interferon-induced depressive disorder group. Significant level was establish at p < 0.05.
Results
During the study period, 46 patients were referred from the dermatology hospitalization department for psychiatric consultation. The dermatological diagnoses were: malignant melanoma in 34 patients, dermatitis in 5 patients, psoriasis in 3 patients, Sézary syndrome in 2 patients, scleroderma in 1 patient and delusion of infestations in 1 patient. Thirty-one patients with malignant melanoma (67%) were treated with IFN-alpha-2b and were included in the current study. The characteristics of the 31 patients with malignant melanoma treated with IFN-alpha-2b were: 19 (61.2%) were females and 12 (38.7%) were males; 5 (16%) aged less than 30 years, 13 (41.9%) aged 30-49 years and 13 (41.8%) aged 50 years or older. Reason for referral were depressive and/or anxiety symptoms in twenty-four patients (77.4%), behavior disorders in five patients (16.1%), and insomnia in two patients (6.5%). The main DSM-IV-TR diagnoses were depressive adjustment disorders in 14 patients (45.16%), followed by IFN-induced depressive disorders in 6 patients (19.36%), anxiety disorders in four patients (12.9%), delirium in three patients (9.68%), personality disorders in two patients (6.45%) and no psychiatric diagnosis in two patients (6.45%). Thirteen patients had lifetime psychiatric diagnoses: 5 patients had mixed depressive-anxiety adjustment disorders prior to the melanoma diagnosis; 4 patients had major depressive disorders; 2 patients had generalized anxiety disorders and 2 patients had personality disorders. Depending on the stage of the malignant melanoma, the IFN-alpha-2b treatment regimen was different. All patients for a resected stage II/III melanoma (51.5%), were treated with a high-dose regimen involving an induction phase of intravenous IFN-alpha-2b 20 MU/m agents. Patients in stage IV (48.3%) were treated with interferon in combination with chemotherapy. The average time of hospitalization was 17 (4.1) days. Table 1 shows comparisons of the two main diagnosis groups: adjustment depressive disorder and IFN-induced depressive disorder.
Discussion
Interferon-alpha is of high interest in the adjuvant treatment of malignant melanoma but psychiatric side effects can occur and lead to a reduction or discontinuation of treatment [2] . In the present series of 31 inpatients with malignant melanoma treated with interferon and referred for psychiatric consultation, depression was the most common diagnosis, more than half of the sample. A primary disorder, adjustment depressive disorder, was the most common psychiatric diagnosis. Several studies have shown that half of all cancer patients have a psychiatric disorder, usually an adjustment disorder with depression [18] . IFN-induced depression occurred in a few patients, which in turn were the most severe. Other patients treated with IFN-alpha, such as chronic hepatitis C patients, have shown a greater prevalence of IFNinduced depression [7] . Nevertheless, the results of the study are in accordance with a recent study showing fewer psychiatric side effects than anticipated in oncology patients treated with IFN-alpha [19] . Both in primary and secondary depression, clinical management and antidepressant treatment allowed continuation of interferon therapy.
The association of interferon treatment with other psychiatric side effects besides depression is widely reported [8, 9] . Other reasons for referral to psychiatric consultation in our study were anxiety disorders, behavior disorders, insomnia and others. Similarly, it is also difficult to evaluate the role of this drug in the etiology of these symptoms. In these patients, the psychiatrist did not attribute these referral symptoms to the use of interferon. All except one patient showed clinical improvement with antidepressant treatment, and a decrease in the doses of interferon was not needed. The results of the study support that discontinuation of interferon treatment is not usually required if a depressive syndrome is diagnosed. Only in one case of IFN-induced depressive disorder, after counseling with the psychiatrist, was the IFN-alpha dose reduced, but not stopped. Primary depressive disorder was associated with a more advanced melanoma stage (55% in stage IV) but with a lower severity of depression and a poorer therapeutic response than IFN-induced depressive disorder. However, as the majority of adjustment depressive disorders received interferon combined with other adjuvant immunosuppressants, we cannot exclude that these other agents may account for the depressive symptoms. Nevertheless, it is widely recognized that antidepressant treatment, especially selective serotonin reuptake inhibitors (SSRI), in depressive adjustment disorders is effective and well tolerated [20] . A recent review in this field provides evidence that antidepressants cause an improvement in depression, in patients with a wide range of physical diseases, significantly more frequently than either placebo or no treatment [21] . Antidepressant medications should also be considered for the treatment of moderate-to-severe depression in cancer patients [22] . Interferon-induced depressive disorder was associated with a higher initial severity of depressive symptoms, but a lower melanoma stage (II or III) than adjustment depressive disorder. Moreover the psychopharmacological treatment response was better in patients with induceddepressive disorder. In this group, in contrast to the primary depression group, depressive symptoms were rated as much or very much improved at the end of hospitalization. Focusing on the effects of interferon, it is described an antiserotoninergic mechanism. Accordingly, SSRI treatment seems to be a good option for the treatment of IFN-induced depressive disorders [23, 24] . Controlled clinical trials of SSRI in interferon-induced depression are still to be published. Nevertheless, several casereports and naturalistic follow-up studies have documented the usefulness of this group of antidepressants [7, 25, 26] . In summary, in spite of the small sample size and the lack of a control group, this preliminary study found that only a small proportion of hospitalized patients with malignant melanoma treated with interferon had an interferoninduced depressive disorder. These cases were the most severe, however, clinical management and antidepressant treatment allowed continuation of interferon therapy. Future longitudinal consultation-liaison studies with larger controlled samples will help in understanding the relationship between depression and adjuvant interferon treatment in melanoma patients. ■
